Диссертация (1139747), страница 25
Текст из файла (страница 25)
Catch-up growth duringtocilizumab therapy for systemic juvenile idiopathic arthritis: results from aphase III trial. // Arthritis Rheumatol. 2015 Mar;67(3):840-8. doi:10.1002/art.3898447.De Benedetti F, Meazza C, Martini A. Role of interleukin-6 in growthfailure: an animal model. // Horm Res. 2002;58 Suppl 1:24-748.Del Pozo E, Zapf J, Mackenzie AR, Janner M, Perrelet R, Lippuner K,Mullis P. Experimental arthritis: effect on growth parameters and total skeletalcalcium.HormIGFRes.2009Oct;19(5):442-6.doi:10.1016/j.ghir.2009.01.003. Epub 2009 Feb 2549.Deodati A., Cianfarani S.. Impact of growth hormone therapy on adultheight of children with idiopathic short stature: systematic review //BMJ2011;342: 715750.Deslandre C.
Juvenile idiopathic arthritis: Definition and classification.Arch Pediatr. 2016 Apr;23(4):437-41. doi: 10.1016/j.arcped.2016.01.005.Epub 2016 Mar 851.Eisenstein E. M., Berkun Y. Diagnosis and classification of juvenileidiopathic arthritis // Journal of Autoimmunity 48-49 (2014) 31-3314452.El Badri D, Rostom S, Bouaddi I, Hassani A, Chkirate B, Amine B,Hajjaj-Hassouni N. Sexual maturation in Moroccan patients with juvenileidiopathic arthritis. // Rheumatol Int. 2014 May;34(5):665-8.
doi:10.1007/s00296-013-2737-9. Epub 2013 Apr 453.Frampton JE. Tocilizumab: a review of its use in the treatment ofjuvenile idiopathic arthritis. //Paediatr Drugs. 2013 Dec;15(6):515-31. doi:10.1007/s40272-013-0053-154.García-Consuegra Molina J, Merino Muñoz R, Lama More R, CoyaViña J, Gracia Bouthelier R.
Growth in children with juvenile idiopathicarthritis // An Pediatr (Barc). 2003 Jun;58(6):529-3755.Gaspari S, Marcovecchio ML, Breda L, Chiarelli F. Growth in juvenileidiopathic arthritis: the role of inflammation. // Clin Exp Rheumatol. 2011Jan-Feb;29(1):104-10. Epub 2011 Feb 2356.Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE,Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW. Effectsof long-term etanercept treatment on growth in children with selectedcategories of juvenile idiopathic arthritis.
// Arthritis Rheum. 2010Nov;62(11):3259-64. doi: 10.1002/art.2768257.Giustina A., Mazziotti G., Canalis E. Growth Hormone, Insulin-LikeGrowth Factors, and the Skeleton // Endocrine Reviews 2008: 29(5): 535–55958.Goldzweig O, Hashkes PJ, Abatacept in the treatment of polyarticularJIA: development, clinical utility, and place in therapy. // Drug Des DevelTher. 2011 Jan 26;5:61-70. doi: 10.2147/DDDT.S1648959.Górska A, Urban M, Konstantynowicz J, Bartnicka M, Chlabicz S,Górski S, Kaczmarski M. Relationship between bone mineral content andgrowth disorders in children with juvenile idiopathic arthritis // Pol MerkurLekarski.
2008 Mar;24(141):227-3014560.Greulich W.W., Pyle S.I. / Атлас рентгенограмм кисти и предплечья(оценка костного возраста) // электронная версия, CD, 1970, Лондон,Оксфорд61.Guo L, Lu MP, Tang YM, Teng LP, Xu YP, Zou LX, Zheng RJ, ZhengQ. Serum cytokine levels in children with newly diagnosed active systemicjuvenile idiopathic arthritis. // Zhongguo Dang Dai Er Ke Za Zhi.
2014Dec;16(12):1241-462.Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM,Wu JJ, Herrinton LJ. Incidence and prevalence of juvenile idiopathic arthritisamong children in a managed care population, 1996-2009. // J Rheumatol.2013 Jul;40(7):1218-25. doi: 10.3899/jrheum.120661. Epub 2013 Apr 1563.Herlin T.Tocilizumab for the treatment of systemic juvenile idiopathicarthritis.
//Expert Rev Clin Immunol. 2012 Aug;8(6):517-2564.Herlin T1. Tocilizumab: The evidence for its place in the treatment ofjuvenile idiopathic arthritis. // Core Evid. 2010 Jun 15;4:181-965.Horneff G, Update on biologicals for treatment of juvenile idiopathicarthritis.//ExpertOpinBiolTher.2013Mar;13(3):361-76.doi:10.1517/14712598.2013.735657. Epub 2013 Jan 566.Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T,Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, MoriM, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S. Efficacy,pharmacokinetics, and safety of adalimumab in pediatric patients withjuvenileidiopathicarthritisinJapan.//ClinRheumatol.2012Dec;31(12):1713-21.
doi: 10.1007/s10067-012-2082-5. Epub 2012 Oct 2.67.Kahn PJ. Juvenile idiopathic arthritis - what the clinician needs to know.// Bull Hosp Jt Dis (2013). 2013;71(3):194-968.Kaminiarczyk-Pyzalka D, Adamczak K, Mikos H, Klimecka I, MoczkoJ, Niedziela M. Proinflammatory cytokines in monitoring the course ofdisease and effectiveness of treatment with etanercept (ETN) of children with146oligo- and polyarticular juvenile idiopathic arthritis (JIA).
// Clin Lab.2014;60(9):1481-9069.Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR;British Society for Paediatric and Adolescent Rheumatology EtanerceptCohort Study, Growth in children and adolescents with juvenile idiopathicarthritis over 2 years of treatment with etanercept: results from the BritishSociety for Paediatric and Adolescent Rheumatology Etanercept CohortStudy.//Rheumatology(Oxford).2015Jul;54(7):1279-85.doi:10.1093/rheumatology/keu489. Epub 2015 Jan 3070.Keating GM, Abatacept: a review of its use in the management ofrheumatoidarthritis.//Drugs.2013Jul;73(10):1095-119.doi:10.1007/s40265-013-0080-971.Kessler EA, Becker ML. Therapeutic advancements in juvenileidiopathic arthritis.
//Best Pract Res Clin Rheumatol. 2014 Apr;28(2):293313. doi: 10.1016/j.berh.2014.03.00572.Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, KupperH. Safety, effectiveness, and pharmacokinetics of adalimumab in childrenwith polyarticular juvenile idiopathic arthritis aged 2 to 4 years. // ClinRheumatol. 2014;33(10):1433-41. doi: 10.1007/s10067-014-2498-1. Epub2014 Feb 2. 73.Konopelko O. U., Zholobova E. S., Rozvadovskaya O. S.
Dynamics oflongitudinal growth in children with idiopathic rheumatoid arthritis inresponse to infliximab treatment // Pediatr. Rheumatol. 2011. Vol. 9. Supple1. P. S16574.Kröger L, Putto-Laurila A, Vähäsalo P, Malin M, Aalto K. Still'sdisease--juvenilearthritiswithsystemiconset.//Duodecim.2014;130(16):1615-21. 75.Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treatjuvenile idiopathic arthritis.
//Biologics. 2008 Dec;2(4):865-7414776.Liem JJ, Rosenberg AM. Growth patterns in juvenile rheumatoidarthritis. // Clin Exp Rheumatol. 2003 Sep-Oct;21(5):663-877.Lovell Daniel J., Nicolino Ruperto, Steven Goodman, Andreas Reiff,Lawrence Jung, Katerina Jarosova, Dana Nemcova, Richard Mouy, ChristySandborg, John Bohnsack, Dirk Elewaut, Ivan Foeldvari, Valeria Gerloni,Jozef Rovensky, Kirsten Minden, Richard K.
Vehe, L. Wagner Weiner, GerdHorneff, Hans-Iko Huppertz, Nancy Y. Olson, John R. Medich, RobertoCarcereri-De-Prati, Melissa J. McIlraith, Edward H. Giannini, and AlbertoMartini. Adalimumab with or without Methotrexate in Juvenile RheumatoidArthritis. // N Engl J Med 2008; 359:810-20 DOI: 10.1056/NEJMoa070629078.Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-MagalhaesC, Chavez-Corrales J, Huemer C13, Kivitz A, Blanco FJ, Foeldvari I, HoferM, Huppertz HI, Job Deslandre C, et all., Long-term safety, efficacy, andquality of life in patients with juvenile idiopathic arthritis treated withintravenous abatacept for up to seven years.
// Arthritis Rheumatol. 2015Oct;67(10):2759-70. doi: 10.1002/art.3923479.Lui J. C., Baron J. Effects of glucocorticoids on the growth plate //Endocr. Dev. 2011. 20. P. 187–19380.Lurati A, Cimaz R, Gattinara M, Gerloni V, Teruzzi B, Salmaso A,Fantini F. Skeletal mineralization in a prepubertal female population affectedby juvenile idiopathic arthritis // Reumatismo.
2008 Jul-Sep;60(3):224-981.MacRae V. E., Wong S. C., Farquharson C., Ahmed S. F. Cytokineactions in growth disorders associated with pediatric chronic inflammatorydiseases (review) // Int. J. Mol. Med. 2006. Vol. 18. N 6. P. 1011‒101882.MacRae VE, Farquharson C, Ahmed SF. The pathophysiology of thegrowth plate in juvenile idiopathic arthritis. // Rheumatology (Oxford). 2006Jan;45(1):11-9.
Epub 2005 Sep 783.MacRae VE, Wong SC, Smith W, Gracie A, McInnes I, Galea P,Gardner-Medwin J, Farquharson C, Ahmed SF. Cytokine profiling and in148vitro studies of murine bone growth using biological fluids from children withjuvenile idiopathic arthritis. // Clin Endocrinol (Oxf). 2007 Sep;67(3):442-8.Epub 2007 Jun 784.Makay B., E. Unsal, O. Kasapcopur Juvenile idiopathic arthritis / //World J Rheumatol 2013 November 12; 3(3): 16-2485.Malattia C., Martini A. Glucocorticoids in juvenile idiopathic arthritis// Ann. N.
Y. Acad. Sci. 2014. Vol. 1318. P. 65‒7086.Mannion ML, Xie F, Curtis JR, Beukelman T, Recent trends inmedication usage for the treatment of juvenile idiopathic arthritis and theinfluence of tumor necrosis factor inhibitors.// J Rheumatol. 2014Oct;41(10):2078-84. doi: 10.3899/jrheum.140012.
Epub 2014 Aug 187.Mårtensson K., D.Chrysis, L. Savendahl. Interleukin-1 and TNF- Actin Synergy to Inhibit Longitudinal Growth in Fetal Rat Metatarsal Bones / //Journal of Bone and Mineral Research, Vol. 19, № 11, 2004, 1805-181288.Militaru A. S., Daeseu C., Simedria I., Maginean O., Sabau I.Correlations Between Clinical Forms and Biomarkers in Juvenile IdiopathicArthritis // Annals of RSCB Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
